Randomised controlled clinical trial of masitinib in Alzheimer’s Disease.
Clinical trial (phase 3) to test efficacy and safety of daily oral masitinib, over the course of 24 weeks, in the treatment of patients with mild-moderate Alzheimer’s Disease.
Those interested must have a probable diagnosis of mild to moderate Alzheimer’s Disease (sMMSE score of 12-25), be currently taking donepezil, rivastigmine or galantamine memantine, have a spouse/ family member/ carer or friend willing to assist in the trial and be aged 50 or over.
Participants will be prescribed the study medication for 24 weeks. All clinical trials are randomised controlled trials (RCTs). This means that participants are randomly assigned to take one of several doses, including a placebo. More information on this will be provided before you agree to take part.
The trial also involves regular appointments with our clinical trial staff for physical monitoring and assessment purposes.
If you are interested in the study or would like some more information, please contact Helen Adams, Clinical Research Coordinator, on 01932 7222 47/ 07867 142 173 or email@example.com. Alternatively you can contact the Principle Investigator Dr Ramin Nilforooshan.